Funded in part by Blackmores Australia Ltd.
Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial
Parker HM, Cohn JS, O'Connor HT, Garg ML, Caterson ID, George J, Johnson NA
Nutrients · 34 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Company
- Blackmores Australia Ltd.
Based on 1 listed funder(s).
Publication
- Published
- 2019-02-23 · Nutrients · vol. 11 · issue 2 · p. 475
- Publisher
- Multidisciplinary Digital Publishing Institute
- Cited
- 52 citations · more than 96% of similar papers · 5.1× the field average
- Impact
- Top 10% most cited in its field
- References
- 63 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Liver Disease Diagnosis and Treatment · Fatty Acid Research and Health · Diet, Metabolism, and Disease
- Keywords
- Fish oil, Medicine, Fatty liver, Internal medicine, Overweight, Placebo, Randomized controlled trial, Polyunsaturated fatty acid, Endocrinology, Adipose tissue, Nonalcoholic fatty liver disease, Gastroenterology, Obesity, Physiology, Biology, Fatty acid, Pathology, Disease, Biochemistry
- MeSH
- liver, humans, fatty acids, omega-3, fish oils, body composition, dietary supplements, adult, male, intra-abdominal fat, overweight, non-alcoholic fatty liver disease
7 authors
From AU
- Helen M. Parker · correspondingThe University of Sydney
- Jeffrey S. CohnThe Heart Research Institute
- Helen T O'ConnorThe University of Sydney
- Manohar L. GargUniversity of Newcastle Australia
- Ian Douglas CatersonThe University of Sydney
- Jacob GeorgeThe University of Sydney; Westmead Institute; Westmead Institute for Medical Research
Abstract
Being overweight increases the risk of the development of metabolic conditions such as non-alcoholic fatty liver disease (NAFLD), which is itself an independent predictor of cardiovascular disease. Omega-3 polyunsaturated fatty acid (PUFA) supplementation is recommended for prevention of chronic disease, and is thought to reduce raised liver fat, yet there have been few randomized controlled trials with accurate measurement of liver fat. We assessed the effect of 12 weeks of supplementation with omega-3 PUFA from fish oil versus placebo on quantified liver fat, liver tests, and body composition including visceral adipose tissue (VAT) in a double-blind randomized controlled trial. Fifty apparently healthy overweight men (BMI 25.0⁻29.9 kg/m²; waist > 94 cm) were randomly allocated to consume fish oil (total daily dose: 1728 mg marine triglycerides, of which 588 mg EPA and 412 mg DHA, combined with 200 mg antioxidant, coenzyme Q10) or placebo (olive oil capsules) daily for 12 weeks. Liver fat was assessed using proton magnetic resonance spectroscopy. All outcomes were assessed at baseline and following 6 and 12 weeks of supplementation. Baseline liver fat was 4.6 ± 0.5% (range: 0.6 to 18.2%); 16 (32%) participants met the criteria for NAFLD (>5.5% liver fat). Repeated measures ANOVA revealed no significant time or group × time effect for fish oil versus placebo for liver fat, liver enzymes, anthropometry, or body composition including VAT (p > 0.05 for all), with similar finding for sub-analysis of participants with NAFLD. Omega-3 PUFA did not appear to be an effective agent for reducing liver fat in overweight men. The factors determining the health benefits of omega-3 PUFA supplementation on an individual level need to be clarified.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.